Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Pazopanib

7ee4e6e8-ce70-5fa1-b8cb-82ff1b5124e1 · FDA Approved · targets FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2

Pazopanib

MeasuredReference

Pazopanib targets FLT4_VEGFR3, TNIK, RAF1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

FLT4_VEGFR3TNIKRAF1MLK3_MAP3K11FLT1_VEGFR1

Top hallmarks

  • tumor promoting inflammation4.0k
  • proliferation3.4k
  • evading apoptosis3.1k

Top pathways disrupted

  • pi3k akt mtor signaling8.2k
  • apical junction7.9k
  • allograft rejection7.3k

Resistance landscape — Pazopanib

MeasuredReference

1 known oncogenic variants exist on Pazopanib's top targets — see detail for inhibition impact.

Open in new tab